According to Endo International 's latest financial reports the company's current revenue (TTM) is $2.01 B. In 2022 the company made a revenue of $2.31 B a decrease over the years 2021 revenue that were of $2.99 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $2.01 B | -13.25% |
2022 | $2.31 B | -22.53% |
2021 | $2.99 B | 3.1% |
2020 | $2.90 B | -0.39% |
2019 | $2.91 B | -1.11% |
2018 | $2.94 B | -15.04% |
2017 | $3.46 B | -13.5% |
2016 | $4.01 B | 22.69% |
2015 | $3.26 B | 29.83% |
2014 | $2.51 B | 2.39% |
2013 | $2.45 B | -18.78% |
2012 | $3.02 B | 10.89% |
2011 | $2.73 B | 59.08% |
2010 | $1.71 B | 17.48% |
2009 | $1.46 B | 15.89% |
2008 | $1.26 B | 16.11% |
2007 | $1.08 B | 19.34% |
2006 | $0.90 B | 10.91% |
2005 | $0.82 B | 33.34% |
2004 | $0.61 B | 3.27% |
2003 | $0.59 B | 49.29% |
2002 | $0.39 B | 58.34% |
2001 | $0.25 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Zogenix ZGNX | $81.69 M | -95.94% | ๐บ๐ธ USA |
Cara Therapeutics
CARA | $20.96 M | -98.96% | ๐บ๐ธ USA |